Welcome to the Takeda Oncology Newsroom. This section is dedicated to providing the most up-to-date information about our company, our people and our science.
If you are a reporter, please contact:
Phone: 617-444-1400
Email: TakedaOncologyNews@takeda.com
For other Takeda news releases, please visit the Takeda.com Newsroom.
Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma
Takeda Announces U.S. FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO™ (ixazomib) in Multiple Myeloma as a First-Line Maintenance Therapy
